Published in Oncology on June 08, 2010
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med (2015) 1.83
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant (2015) 1.38
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics (2015) 1.11
Novel approaches to inhibit HIV entry. Viruses (2012) 1.00
Biased and g protein-independent signaling of chemokine receptors. Front Immunol (2014) 0.96
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood (2011) 0.94
Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther (2011) 0.84
Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol Med (2012) 0.84
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher (2012) 0.84
Chemokine receptors in epithelial ovarian cancer. Int J Mol Sci (2013) 0.84
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol (2011) 0.83
The pharmacology of regenerative medicine. Pharmacol Rev (2013) 0.83
Examination of structure-activity relationship of viologen-based dendrimers as CXCR4 antagonists and gene carriers. Bioconjug Chem (2014) 0.83
Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies. Adv Exp Med Biol (2012) 0.83
Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev (2016) 0.78
Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med (2013) 0.76
Targeting chemokine receptors in disease - a case study of CCR4. Eur J Pharmacol (2015) 0.75
Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma. Oncol Lett (2015) 0.75
Effect of endogenous bone marrow derived stem cells induced by AMD-3100 on expanded ischemic flap. J Korean Med Sci (2014) 0.75
Plerixafor. J Adv Pract Oncol (2012) 0.75
Combinatorial G-CSF/AMD3100 treatment in cardiac repair after myocardial infarction. PLoS One (2014) 0.75
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Allelic variation in human gene expression. Science (2002) 11.42
Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res (2007) 7.87
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
DATF: a database of Arabidopsis transcription factors. Bioinformatics (2005) 4.34
Analysis of transcription factor HY5 genomic binding sites revealed its hierarchical role in light regulation of development. Plant Cell (2007) 4.13
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol (2010) 3.49
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol (2004) 3.18
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98
Integration of brassinosteroid signal transduction with the transcription network for plant growth regulation in Arabidopsis. Dev Cell (2010) 2.96
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst (2011) 2.74
Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med (2012) 2.69
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet (2011) 2.67
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res (2004) 2.24
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
PlantTFDB: a comprehensive plant transcription factor database. Nucleic Acids Res (2007) 2.17
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res (2006) 2.07
Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst (2004) 2.07
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 2.06
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res (2005) 1.93
High-resolution mapping of epigenetic modifications of the rice genome uncovers interplay between DNA methylation, histone methylation, and gene expression. Plant Cell (2008) 1.85
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist (2005) 1.81
Global genome expression analysis of rice in response to drought and high-salinity stresses in shoot, flag leaf, and panicle. Plant Mol Biol (2007) 1.76
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 1.63
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer (2014) 1.51
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
Inferring gene regulatory networks from gene expression data by path consistency algorithm based on conditional mutual information. Bioinformatics (2011) 1.45
FDA drug approval summary: panitumumab (Vectibix). Oncologist (2007) 1.44
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res (2012) 1.41
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
FDA drug approval summaries: pemetrexed (Alimta). Oncologist (2004) 1.37
A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem (2004) 1.37
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36
2-(4,5-Diphenyl-2-p-tolyl-1H-imidazol-1-yl)-3-phenyl-propan-1-ol. Acta Crystallogr Sect E Struct Rep Online (2012) 1.35
Genome-wide profiling of histone H3 lysine 9 acetylation and dimethylation in Arabidopsis reveals correlation between multiple histone marks and gene expression. Plant Mol Biol (2010) 1.33
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.31
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol (2007) 1.29
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res (2005) 1.28
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist (2010) 1.25
FDA drug approval summaries: oxaliplatin. Oncologist (2004) 1.25
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist (2010) 1.25